Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02966756 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02966756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02966756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 12, 2017
Completion date
December 31, 2030
Enrollment
66 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), small lymphocytic lymphoma (sll)